全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Single Versus Double Dose Praziquantel Comparison on Efficacy and Schistosoma mansoni Re-Infection in Preschool-Age Children in Uganda: A Randomized Controlled Trial

DOI: 10.1371/journal.pntd.0003796

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Schistosoma mansoni infection is proven to be a major health problem of preschool-age children in sub-Saharan Africa, yet this age category is not part of the schistosomiasis control program. The objective of this study was to compare the impact of single and double dose praziquantel (PZQ) treatment on cure rates (CRs), egg reduction rates (ERRs) and re-infection rates 8 months later, in children aged 1-5 years living along Lake Victoria, Uganda. Methodology/Principal Findings Infected children (n= 1017) were randomized to receive either a single or double dose of PZQ. Initially all children were treated with a single standard oral dose 40 mg/kg body weight of PZQ. Two weeks later a second dose was administered to children in the double dose treatment arm. Side effects were monitored at 30 minutes to 24 hours after each treatment. Efficacy in terms of CRs and ERRs for the two treatments was assessed and compared 1 month after the second treatment. Re-infection with S. mansoni was assessed in the same children 8 months following the second treatment. CRs were non-significantly higher in children treated with two 40 mg/kg PZQ doses (85.5%; 290/339) compared to a single dose (83.2%; 297/357). ERRs were significantly higher in the double dose with 99.3 (95%CI: 99.2-99.5) compared with 98.9 (95%CI: 98.7-99.1) using a single dose, (P = 0.01). Side effects occurred more frequently during the first round of drug administration and were mild and short-lived; these included vomiting, abdominal pain and bloody diarrhea. Overall re-infection rate 8 months post treatment was 44.5%. Conclusions PZQ is efficacious and relatively safe to use in preschool-age children but there is still an unmet need to improve its formulation to suit small children. Two PZQ doses lead to significant reduction in egg excretion compared to a single dose. Re-infection rates with S. mansoni 8 months post treatment is the same among children irrespective of the treatment regimen.

 References

[1]  Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Sachs SE, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med. 2006;3(5):e102. pmid:16435908 doi: 10.1371/journal.pmed.0030102
[2]  Molyneux DH, Hotez PJ, Fenwick A. “Rapid-impact interventions”: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med. 2005;2(11):e336. pmid:16212468 doi: 10.1371/journal.pmed.0020336
[3]  Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6(7):411–25. pmid:16790382 doi: 10.1016/s1473-3099(06)70521-7
[4]  van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JDF, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003;86(2):125–39. doi: 10.1016/s0001-706x(03)00029-9
[5]  Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop. 2000;77(1):41–51. pmid:10996119 doi: 10.1016/s0001-706x(00)00122-4
[6]  Loewenberg S. Uganda's struggle with schistosomiasis. Lancet. 2014;383(9930):1707–8. pmid:24843875 doi: 10.1016/s0140-6736(14)60817-5
[7]  Savioli L, Gabrielli A, Montresor A, Chitsulo L, Engels D. Schistosomiasis control in Africa: 8 years after World Health Assembly Resolution 54· 19. Parasitology. 2009;136(13):1677–81. doi: 10.1017/S0031182009991181. pmid:19765347
[8]  WHO. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: World Health Organization; 2002. pmid:12592987
[9]  Bosompem K, Bentum IA, Otchere J, Anyan W, Brown C, Osada Y, et al. Infant schistosomiasis in Ghana: a survey in an irrigation community. Trop Med Int Health. 2004;9(8):917–22. pmid:15303998 doi: 10.1111/j.1365-3156.2004.01282.x
[10]  Nalugwa A, Olsen A, Tukahebwa M, Nuwaha F. Intestinal schistosomiasis among preschool children along the shores of Lake Victoria in Uganda. Acta Trop. 2015;142:115–21. doi: 10.1016/j.actatropica.2014.11.014. pmid:25454166
[11]  Odogwu S, Ramamurthy N, Kabatereine N, Kazibwe F, Tukahebwa E, Webster J, et al. Schistosoma mansoni in infants (aged< 3 years) along the Ugandan shoreline of Lake Victoria. Ann Trop Med Parastol. 2006;100(4):315–26. pmid:16762112 doi: 10.1179/136485906x105552
[12]  Stothard JR, Sousa-Figueiredo JC, Navaratnam AM. Advocacy, policies and practicalities of preventive chemotherapy campaigns for African children with schistosomiasis. 2013. doi: 10.1586/14787210.2013.811931. pmid:23879611
[13]  Montresor A, Stoltzfus RJ, Albonico M, Tielsch JM, Rice AL, Chwaya HM, et al. Is the exclusion of children under 24 months from anthelmintic treatment justifiable? Trans R Soc Trop Med Hyg. 2002;96(2):197–9. pmid:12055814 doi: 10.1016/s0035-9203(02)90303-2
[14]  Utzinger J, Bergquist R, Shu-Hua X, Singer BH, Tanner M. Sustainable schistosomiasis control—the way forward. Lancet. 2003;362(9399):1932–4. pmid:14667754 doi: 10.1016/s0140-6736(03)14968-9
[15]  Keiser J, Ingram K, Utzinger J. Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control. Parasitology. 2011;138(12):1620–32. doi: 10.1017/S0031182011000023. pmid:21349223
[16]  WHO. Report of a meeting to review the results of studies on the treatment of schistosomiasis in preschool-age children. 2011.
[17]  Mutapi F, Rujeni N, Bourke C, Mitchell K, Appleby L, Nausch N, et al. Schistosoma haematobium treatment in 1–5 year old children: safety and efficacy of the antihelminthic drug praziquantel. PLoS Neglect Trop D. 2011;5(5). doi: 10.1371/journal.pntd.0001143
[18]  Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659–67. doi: 10.1097/QCO.0b013e328318978f. pmid:18978535
[19]  Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C. Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Neglect Trop D. 2009;3(1):e357. doi: 10.1371/journal.pntd.0000357. pmid:19159015
[20]  Cioli D, Pica-Mattoccia L, Basso A, Guidi A. Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol. 2014;195(1):23–9. doi: 10.1016/j.molbiopara.2014.06.002. pmid:24955523
[21]  Olliaro P, Delgado-Romero P, Keiser J. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother. 2014;69(4):863–70. doi: 10.1093/jac/dkt491. pmid:24390933
[22]  Fenwick A, Webster JP. Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis. 2006;19(6):577–82. pmid:17075334 doi: 10.1097/01.qco.0000247591.13671.6a
[23]  Crompton DWT. Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers: World Health Organization; 2006.
[24]  Gabrielli A-F, Montresor A, Chitsulo L, Engels D, Savioli L. Preventive chemotherapy in human helminthiasis: theoretical and operational aspects. Trans R Soc Trop Med Hyg. 2011;105(12):683–93. doi: 10.1016/j.trstmh.2011.08.013. pmid:22040463
[25]  Andrews P, Thomas H, Pohlke R, Seubert J. Praziquantel. Medicinal Res Rev. 1983;3(2):147–200. pmid:6408323 doi: 10.1002/med.2610030204
[26]  Cioli D, Pica-Mattoccia L. Praziquantel. Parastol Res. 2003;90(1):S3–S9. pmid:12811543
[27]  Harnett W. The anthelmintic action of praziquantel. Parasitol Today. 1988;4(5):144–6. pmid:15463071 doi: 10.1016/0169-4758(88)90192-5
[28]  Giboda M, Smith J. Schistosoma mansoni eggs as a target for praziquantel: efficacy of oral application in mice. J Trop Med Hyg. 1994;97(2):98–102. pmid:8170010
[29]  Renganathan E, Cioli D. An international initiative on praziquantel use. Parasitol Today. 1998;14(10):390–1. pmid:17040826 doi: 10.1016/s0169-4758(98)01310-6
[30]  Kabatereine NB, Brooker S, Koukounari A, Kazibwe F, Tukahebwa EM, Fleming FM, et al. Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren. Bull World Health Organ. 2007;85(2):91–9. pmid:17308729 doi: 10.2471/blt.06.030353
[31]  Standley CJ, Adriko M, Alinaitwe M, Kazibwe F, Kabatereine NB, Stothard JR. Intestinal schistosomiasis and soil-transmitted helminthiasis in Ugandan schoolchildren: a rapid mapping assessment. Geospat Health. 2009;4(1):39–53. pmid:19908189 doi: 10.4081/gh.2009.209
[32]  Stothard J, Webster B, Weber T, Nyakaana S, Webster J, Kazibwe F, et al. Molecular epidemiology of Schistosoma mansoni in Uganda: DNA barcoding reveals substantial genetic diversity within Lake Albert and Lake Victoria populations. Parasitology. 2009;136(13):1813–24. doi: 10.1017/S003118200999031X. pmid:19627628
[33]  Tukahebwa EM, Magnussen P, Madsen H, Kabatereine NB, Nuwaha F, Wilson S, et al. A very high infection intensity of Schistosoma mansoni in a Ugandan Lake Victoria fishing community is required for association with highly prevalent organ related morbidity. PLoS Neglect Trop D. 2013;7(7):e2268. doi: 10.1371/journal.pntd.0002268. pmid:23936559
[34]  Standley CJ, Wade CM, Stothard JR. A fresh insight into transmission of schistosomiasis: a misleading tale of Biomphalaria in Lake Victoria. PloS one. 2011;6(10):e26563. doi: 10.1371/journal.pone.0026563. pmid:22046308
[35]  Barakat R, Morshedy HE. Efficacy of two praziquantel treatments among primary school children in an area of high Schistosoma mansoni endemicity, Nile Delta, Egypt. Parasitology. 2011;138(04):440–6. doi: 10.1017/s003118201000154x
[36]  Tukahebwa EM, Vennervald BJ, Nuwaha F, Kabatereine NB, Magnussen P. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Trans R Soc Trop Med Hyg. 2013;107(6):397–404. doi: 10.1093/trstmh/trt024. pmid:23596262
[37]  Kirkwood B, Sterne J. Essential Medical Statistics: Wiley; 2003.
[38]  De Vlas S, Gryseels B. Underestimation of Schistosoma mansoni prevalences. Parasitol Today. 1992;8(8):274–7. pmid:15463638 doi: 10.1016/0169-4758(92)90144-q
[39]  De Vlas S, Gryseels B, Van Oortmarssen G, Polderman A, Habbema J. A model for variations in single and repeated egg counts in Schistosoma mansoni infections. Parasitology. 1992;104(03):451–60. doi: 10.1017/s003118200006371x
[40]  Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med Tropl S？o Paulo. 1972;14(6):397–400.
[41]  Olliaro PL, Vaillant M, Hayes DJ, Montresor A, Chitsulo L. Practical dosing of praziquantel for schistosomiasis in preschool-aged children. Trop Med Int Health. 2013;18(9):1085–9. doi: 10.1111/tmi.12152. pmid:23937700
[42]  Coulibaly JT, N'Gbesso YK, Knopp S, Keiser J, N'Goran EK, Utzinger J. Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Neglect Trop D. 2012;6(12):e1917. doi: 10.1371/journal.pntd.0001917. pmid:23236526
[43]  Garba A, Lamine MS, Barkiré N, Djibo A, Sofo B, Gouvras AN, et al. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop. 2013;128(2):334–44. doi: 10.1016/j.actatropica.2012.08.008. pmid:22940014
[44]  Muhumuza S, Olsen A, Katahoire A, Kiragga AN, Nuwaha F. Effectiveness of a Pre-treatment Snack on the Uptake of Mass Treatment for Schistosomiasis in Uganda: A Cluster Randomized Trial. PLoS Med. 2014;11(5):e1001640. doi: 10.1371/journal.pmed.1001640. pmid:24824051
[45]  Vennervald BJ, Booth M, Butterworth AE, Kariuki HC, Kadzo H, Ireri E, et al. Regression of hepatosplenomegaly in Kenyan school-aged children after praziquantel treatment and three years of greatly reduced exposure to Schistosoma mansoni. Trans R Soc Trop Med Hyg. 2005;99(2):150–60. pmid:15607341 doi: 10.1016/j.trstmh.2004.06.009
[46]  Breslow N, Day N. Statistical Methods in Cancer Research: The Analysis of Case-control Studies. v. 1, Scientific Publication 32. Intl Agency Res Cancer. 1980.
[47]  Danso-Appiah A, Olliaro PL, Donegan S, Sinclair D, Utzinger J. Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev. 2013;2. doi: 10.1002/14651858.cd000528.pub2
[48]  Doenhoff MJ, Pica-Mattoccia L. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. 2006.
[49]  Notterman DA, Nardi M, Saslow JG. Effect of dose formulation on isoniazid absorption in two young children. Pediatrics. 1986;77(6):850–2. pmid:3086830
[50]  Standing JF, Tuleu C. Paediatric formulations—Getting to the heart of the problem. Intl J Pharm. 2005;300(1):56–66. doi: 10.1016/j.ijpharm.2005.05.006
[51]  Kabatereine N, Kemijumbi J, Ouma J, Sturrock R, Butterworth A, Madsen H, et al. Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. Trans R Soc Trop Med Hyg. 2003;97(5):599–603. pmid:15307437 doi: 10.1016/s0035-9203(03)80044-5
[52]  Picquet M, Vercruysse J, Shaw DJ, Diop M, Ly A. Efficacy of praziquantel against Schistosoma mansoni in northern Senegal. Trans R Soc Trop Med Hyg. 1998;92(1):90–3. pmid:9692165 doi: 10.1016/s0035-9203(98)90971-3
[53]  Giboda M, Smith J. Schistosoma mansoni eggs as a target for praziquantel: efficacy of oral application in mice. J Trop Med Hyg. 1994;97(2):98–102. pmid:8170010
[54]  Sabah A, Fletcher C, Webbe G, Doenhoff M. Schistosoma mansoni: Chemotherapy of infections of different ages. Exp Parastol. 1986;61(3):294–303. pmid:3086114 doi: 10.1016/0014-4894(86)90184-0
[55]  Montresor A. Cure rate is not a valid indicator for assessing drug efficacy and impact of preventive chemotherapy interventions against schistosomiasis and soil-transmitted helminthiasis. Trans R Soc Trop Med Hyg. 2011;105(7):361–3. doi: 10.1016/j.trstmh.2011.04.003. pmid:21612808
[56]  Utzinger J, N'goran EK, N'dri A, Lengeler C, Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health. 2000;5(11):771–8. pmid:11123824 doi: 10.1046/j.1365-3156.2000.00646.x
[57]  Black CL, Mwinzi PN, Muok EM, Abudho B, Fitzsimmons CM, Dunne DW, et al. Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni. PLoS neglected tropical diseases. 2010;4(3). doi: 10.1371/journal.pntd.0000637
[58]  Woolhouse M, Hagan P. Seeking the ghost of worms past. Nature Med. 1999;5(11). doi: 10.1038/15169
[59]  de Moira AP, Jones FM, Wilson S, Tukahebwa E, Fitzsimmons CM, Mwatha JK, et al. Effects of Treatment on IgE Responses against Parasite Allergen-Like Proteins and Immunity to Reinfection in Childhood Schistosome and Hookworm Coinfections. Infect Immun. 2013;81(1):23–32. doi: 10.1128/IAI.00748-12. pmid:23071136
[60]  Webster M, Fallon P, Fulford A, Butterworth A, Ouma J, Kimani G, et al. Effect of praziquantel and oxamniquine treatment on human isotype responses to Schistosoma mansoni: elevated IgE to adult worm. Parasit Immunol. 1997;19(7):333–5. pmid:9278946 doi: 10.1046/j.1365-3024.1997.d01-211.x
[61]  Butterworth A. Human immunity to schistosomes: some questions. Parasitol Today. 1994;10(10):378–80. pmid:15275540 doi: 10.1016/0169-4758(94)90225-9
[62]  Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosomahaematobium. 1991. pmid:1898985 doi: 10.1038/349243a0
[63]  Mutapi F, Ndhlovu P, Hagan P, Woolhouse M. Changes in specific anti-egg antibody levels following treatment with praziquantel for Schistosoma haematobium infection in children. Parasit Immunol. 1998;20(12):595–600. pmid:9990644 doi: 10.1046/j.1365-3024.1998.00192.x
[64]  Cundill B, Alexander N, Bethony JM, Diemert D, Pullan RL, Brooker S. Rates and intensity of re-infection with human helminths after treatment and the influence of individual, household, and environmental factors in a Brazilian community. Parasitology. 2011;138(11):1406–16. doi: 10.1017/S0031182011001132. pmid:21819640
[65]  Olds G, King C, Hewlett J, Olveda R, Wu G, Ouma J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Diseases. 1999;179(4):996–1003. pmid:10068597 doi: 10.1086/314686
[66]  Raso G, N’Goran EK, Toty A, Luginbühl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western C？te d'Ivoire. Trans R Soc Trop Med Hyg. 2004;98(1):18–27. pmid:14702835 doi: 10.1016/s0035-9203(03)00003-8
[67]  Polderman A, Gryseels B, Gerold J, Mpamila K, Manshande J. Side effects of praziquantel in the treatment of Schistosoma mansoni in Maniema, Zaire. Trans R Soc Trop Med Hyg. 1984;78(6):752–4. pmid:6335929 doi: 10.1016/0035-9203(84)90007-5
[68]  Bj？rklund H, Bylund G. Absorption, distribution and excretion of the anthelmintic praziquantel (Droncit) in rainbow trout (Salmo gairdneri R.). Parastol Res. 1987;73(3):240–4. doi: 10.1007/bf00578511
[69]  Mennella JA, Beauchamp GK. Optimizing oral medications for children. Clin Ther. 2008;30(11):2120–32. doi: 10.1016/j.clinthera.2008.11.018. pmid:19108800
[70]  Schwartz GJ, Mu？oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–37. doi: 10.1681/ASN.2008030287. pmid:19158356
[71]  Richter J. The impact of chemotherapy on morbidity due to schistosomiasis. Acta Trop. 2003;86(2):161–83. doi: 10.1016/s0001-706x(03)00032-9
[72]  Vennervald BJ, Dunne DW. Morbidity in schistosomiasis: an update. Curr Opin Infect Dis. 2004;17(5):439–47. pmid:15353964 doi: 10.1097/00001432-200410000-00009

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133